Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (Hypothesis)

被引:149
作者
Pajeva, IK
Wiese, M
机构
[1] Univ Bonn, Inst Pharm, D-53121 Bonn, Germany
[2] Bulgarian Acad Sci, Ctr Biomed Engn, BU-1113 Sofia, Bulgaria
关键词
D O I
10.1021/jm020941h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A general pharmacophore model of P-glycoprotein (P-gp) drugs is proposed that is based on a highly diverse data set and relates to the verapamil binding site of the protein. It is derived from. structurally different drugs using the program GASP. The pharmacophore model consists of two hydrophobic points, three hydrogen bond (HB) acceptor points, and one HB donor point. Pharmacophore patterns of various drugs are obtained, and different binding modes are presumed for some of them. It is concluded that the binding affinity of the drugs depends on the number of the pharmacophore points simultaneously involved in the interaction with P-gp. On the basis of the obtained results, a hypothesis is proposed to explain the broad structural variety of the P-gp substrates and inhibitors: (i) the verapamil binding site of P-gp has several points that can participate in hydrophobic and HB interactions; (ii) different drugs can interact with different receptor points in different binding modes.
引用
收藏
页码:5671 / 5686
页数:16
相关论文
共 52 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]  
[Anonymous], CAMBR STRUCT DAT VER
[3]  
*BIOB CORP, 1995, CLOGP WIND VERS 1 0
[4]  
Craig P.N., 1990, Comprehensive Medicinal Chemistry, VVolume 6, P237
[5]   Role of P-glycoprotein-mediated secretion in absorptive drug permeability:: An approach using passive membrane permeability and affinity to P-glycoprotein [J].
Doppenschmitt, S ;
Spahn-Langguth, H ;
Regårdh, CG ;
Langguth, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (10) :1067-1072
[6]   Radioligand-binding assay employing P-glycoprotein-overexpressing cells:: Testing drug affinities to the secretory intestinal multidrug transporter [J].
Döppenschmitt, S ;
Spahn-Langguth, H ;
Regårdh, CG ;
Langguth, P .
PHARMACEUTICAL RESEARCH, 1998, 15 (07) :1001-1006
[7]  
Döppenschmitt S, 1999, J PHARMACOL EXP THER, V288, P348
[8]  
Ecker G, 1999, MOL PHARMACOL, V56, P791
[9]   Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry [J].
Ecker, GF ;
Csaszar, E ;
Kopp, S ;
Plagens, B ;
Holzer, W ;
Ernst, W ;
Chiba, P .
MOLECULAR PHARMACOLOGY, 2002, 61 (03) :637-648
[10]   Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein [J].
Ekins, S ;
Kim, RB ;
Leake, BF ;
Dantzig, AH ;
Schuetz, EG ;
Lan, LB ;
Yasuda, K ;
Shepard, RL ;
Winter, MA ;
Schuetz, JD ;
Wikel, JH ;
Wrighton, SA .
MOLECULAR PHARMACOLOGY, 2002, 61 (05) :964-973